Arca
Skip to content
Tools
Tools

Ovarian cancer

Drug research and approvals for ovarian cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 774 studies of ovarian cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 113 drug trials for it since 2013, FDA has 19 approved and 65 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 774
  • Trials authorized in Canada: 113
  • FDA orphan approvals: 19
  • EU medicines: 2

Recruiting now

Newest posted first, of 774 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 13

Phase 3 12 of 51

Phase 2 12 of 207

Phase 1 or earlier 12 of 96

How its trials ended

2,215 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 523 whose ending is known, 28% met their primary endpoint, 10% missed it and 62% stopped early.

  • Completed, result not reported73633%
  • Ongoing65129%
  • Status unknown30514%
  • Met its primary endpoint1467%
  • Stopped: other or unclear1447%
  • Stopped: enrollment or feasibility703%
  • Missed its primary endpoint542%
  • Stopped: sponsor or business decision542%
  • Stopped: lack of efficacy352%
  • Stopped: funding141%
  • Stopped: safety6<1%

Trials authorized in Canada

The 10 newest of 113; search them all in Canada trials
Sep 23, 2026A phase 3, open-label, multicenter, randomized study of raludotatug deruxtecan (MK-5909, r-dxd) with or without bevacizumab versus standard-of-care…Raludotatug deruxtecan (MK-5909) / Avastin (bevacizumab) / Mvasi (bevacizumab)Merck & Co. (MSD)Pending
Aug 26, 2026A randomised, open-label, phase III study of torvutatug samrotecan with or without bevacizumab versus standard of care as second- or third-line maintenance…AZD5335 / Avastin / VegzelmaAstraZeneca PharmaceuticalsPending
Aug 26, 2026A phase 3, randomized, open-label study of raludotatug deruxtecan (mk 5909, r-dxd) maintenance treatment with or without bevacizumab versus standard of care in…Raludotatug deruxtecan (r-dxd) (MK-5909))Merck & Co. (MSD)Pending
Aug 20, 2026A randomised, open-label, phase III study of torvutatug samrotecan in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance…Torvutatug samrotecan (AZD5335) / Avastin (bevacizumab) / Vegzelma (bevacizumab)AstraZeneca PharmaceuticalsPending
Aug 11, 2026A randomized, open-label, phase 3 study of rina-s ± bevacizumab versus investigator's choice of platinum-based chemotherapy ± bevacizumab as 2l treatment in…GEN1184 / Vegzelma / Paclitaxel ribosepharm / Carboplatin hikma / Caelyx…GenmabPending
Jul 29, 2026A randomized, open-label, multicenter, phase 3 study to investigate mocertatug rezetecan with or without bevacizumab in comparison to active observation with…Mocertatug rezetecan (GSK5733584) / Avastin / ZirabevGSKOngoing
Jul 3, 2026A randomized, open-label, multicenter, phase 3 study to investigate mocertatug rezetecan with bevacizumab compared with platinum doublet with bevacizumab in…Mocertatug rezetecan (GSK5733584), paclitaxel, carboplatin,…GSKOngoing
Jun 11, 2026A phase 3, randomized, open-label study of INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with…INCB123667IncyteOngoing
May 29, 2026A randomized, open-label, phase 3 study of rinatabart sesutecan (rina-s) plus standard of care versus standard of care as maintenance treatment after 2l…Rinatabart sesutecan (rina-s, PRO1184, GEN1184) / VegzelmaGenmabPending
May 22, 2026A multicenter, first-in-human, dose escalation and optimization phase I/IIa study to investigate safety, tolerability, pharmacokinetics, and efficacy of the…TUB-040Tubulis GmbHPending

FDA orphan designations

Approved first, then open designations, newest first; 15 of 84
May 8, 2025Avmapki Fakzynja Co-PackTreatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapyVerastem, Inc.Approved
Nov 14, 2022ElahereTreatment of adult patients with folate receptor-alpha (FR?) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary…ImmunoGen, Inc.Approved
Nov 29, 2021CytaluxAs an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancerOn Target Laboratories, Inc.Approved
May 8, 2020LynparzaLynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian,…AstraZeneca Pharmaceuticals LPApproved
Apr 29, 2020ZejulaZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal…GlaxoSmithKline, LLC.Approved
Oct 23, 2019ZejulaZEJULA? is indicated for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been…GlaxoSmithKline, LLC.Approved
Dec 19, 2018LynparzaLynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic…AstraZeneca Pharmaceuticals LPApproved
Jun 13, 2018AvastinAvastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients…Genentech, Inc.Approved
Apr 6, 2018RubracaFor the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in…pharma&Approved
Aug 17, 2017LynparzaMaintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a…AstraZeneca Pharmaceuticals LPApproved
Mar 27, 2017ZejulaIndicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who…GlaxoSmithKline, LLC.Approved
Dec 19, 2016RubracaAs monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer…pharma&Approved
Dec 6, 2016AvastinAvastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with…Genentech, Inc.Approved
Dec 19, 2014LynparzaIndicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test)…AstraZeneca Pharmaceuticals LPApproved
Nov 14, 2014AvastinIn combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent…Genentech, Inc.Approved

Medicines authorised in the EU

Newest first
Dec 16, 2014LynparzaOlaparibAstraZeneca ABEMA ↗
Jun 20, 1996Caelyx pegylated liposomalDoxorubicinBaxter Holding B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.